Michael Rudnicki
Founder at SATELLOS BIOSCIENCE INC.
Net worth: 1 M $ as of 30/04/2024
Profile
Michael Rudnicki founded Fate Therapeutics, Inc. in 2007, Satellos Bioscience, Inc. in 2018, where he worked as Director & Chief Scientific Officer, and Satellos Bioscience, Inc. in 2018, where he is working as Chief Discovery Officer.
Dr. Rudnicki also founded Verio Therapeutics, Inc. Dr. Rudnicki also currently works at Ottawa Hospital Research Institute, as Director-Sprott Centre for Stem Cell Research, Stem Cell Network, as Scientific Director, and the University of Ottawa, as Professor.
Dr. Rudnicki also formerly worked at The Ontario Institute For Regenerative Medicine, as Director.
Dr. Rudnicki received his undergraduate degree and doctorate degree from the University of Ottawa.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SATELLOS BIOSCIENCE INC
2.73% | 01/06/2023 | 3,084,220 ( 2.73% ) | 1 M $ | 30/04/2024 |
Michael Rudnicki active positions
| Companies | Position | Start |
|---|---|---|
| SATELLOS BIOSCIENCE INC. | Founder | 01/01/2018 |
| University of Ottawa | Corporate Officer/Principal | - |
Ottawa Hospital Research Institute
 Ottawa Hospital Research Institute Hospital/Nursing ManagementHealth Services The Ottawa Hospital Research Institute is based in Ottawa, CA. The Canadian company provides world-class care with compassionate people. | Corporate Officer/Principal | - |
| Stem Cell Network | Corporate Officer/Principal | - |
Former positions of Michael Rudnicki
| Companies | Position | End |
|---|---|---|
Verio Therapeutics, Inc.
 Verio Therapeutics, Inc. BiotechnologyHealth Technology Part of Fate Therapeutics, Inc., Verio Therapeutics, Inc. is a Canadian pharmaceutical company that manufactures products for activating endogenous stem cells. The company is based in Ottawa, Canada. Verio Therapeutics was acquired by Fate Therapeutics, Inc. on April 08, 2010. The company was founded by Frank Gleeson, Michael Rudnicki. | Founder | - |
The Ontario Institute For Regenerative Medicine
 The Ontario Institute For Regenerative Medicine Miscellaneous Commercial ServicesCommercial Services The Ontario Institute For Regenerative Medicine provides stem cell and regenerative medicine research services. The company was founded by on November 25, 2014 and is headquartered in Toronto, Canada. | Director/Board Member | - |
Satellos Bioscience, Inc. /Old/
 Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Founder | - |
| FATE THERAPEUTICS, INC. | Founder | - |
Training of Michael Rudnicki
| University of Ottawa | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| FATE THERAPEUTICS, INC. | Health Technology |
| SATELLOS BIOSCIENCE INC. | Health Technology |
| Private companies | 5 |
|---|---|
Ottawa Hospital Research Institute
Ottawa Hospital Research Institute Hospital/Nursing ManagementHealth Services The Ottawa Hospital Research Institute is based in Ottawa, CA. The Canadian company provides world-class care with compassionate people. | Health Services |
Verio Therapeutics, Inc.
Verio Therapeutics, Inc. BiotechnologyHealth Technology Part of Fate Therapeutics, Inc., Verio Therapeutics, Inc. is a Canadian pharmaceutical company that manufactures products for activating endogenous stem cells. The company is based in Ottawa, Canada. Verio Therapeutics was acquired by Fate Therapeutics, Inc. on April 08, 2010. The company was founded by Frank Gleeson, Michael Rudnicki. | Health Technology |
The Ontario Institute For Regenerative Medicine
The Ontario Institute For Regenerative Medicine Miscellaneous Commercial ServicesCommercial Services The Ontario Institute For Regenerative Medicine provides stem cell and regenerative medicine research services. The company was founded by on November 25, 2014 and is headquartered in Toronto, Canada. | Commercial Services |
Satellos Bioscience, Inc. /Old/
Satellos Bioscience, Inc. /Old/ BiotechnologyHealth Technology Satellos Bioscience, Inc. is a regenerative medicine company. The firm is dedicated to developing novel therapeutics that stimulates or restore muscle regeneration in severe disorders. The company focuses on the discovery that dysregulated muscle stem-cell polarity a process that balances replenishment of muscle stem cells and production of specialized tissue cells can lead to the inability of the body to properly repair and regenerate muscle throughout life. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which the firm has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. It applies its proprietary MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated. Satellos also maintains the rights to two clinical stage legacy assets as a result of the reverse takeover of iCo Therapeutics Inc.: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada. | Health Technology |
| Stem Cell Network |
- Stock Market
- Insiders
- Michael Rudnicki
